Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET
Company Participants
Sara Pellegrino – SVP, IR and Corporate Communications
Fred Vogt – Interim CEO and President
Dan Kirby – CCO
Igor Bilinsky – COO
Jean-Marc Bellemin – CFO
Friedrich Graf Finckenstein – CMO
Brian Gastman – EVP, Medical Affairs
Conference Call Participants
Andrew Tsai – Jefferies
Tyler Van Buren – TD Cowen
Salim Syed – Mizuho
Andrea Newkirk – Goldman Sachs
Yanan Zhu – Wells Fargo
Colleen Kusy – Baird
Peter Lawson – Barclays
Reni Benjamin – Citizens
Operator
Good day and thank you for standing by. Welcome everyone to the Iovance Biotherapeutics First Quarter 2025 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Sara Pellegrino, SVP, IR and Corporate Communications. Please go ahead.
Sara Pellegrino
Good afternoon and thank you for joining the Iovance conference call and webcast to discuss our first quarter 2025 financial results, as well as recent corporate updates.
Dr. Fred Vogt, our Interim Chief Executive Officer and President will provide an introduction and focus on the U.S. Commercial launch of Amtagvi, including revenue and revenue guidance.
Dan Kirby, Chief Commercial Officer, will discuss the Amtagvi commercial launch; Dr. Igor Bilinsky, our Chief Operating Officer, will provide a manufacturing update. Jean-Marc Bellemin, our CFO, will review our financial results, including revenue and revenue guidance, gross margin, and cash burn guidance; and Dr. Friedrich Finckenstein, our Chief Medical Officer, will summarize key pipeline programs.
Additional members of our leadership team, including Dr. Raj Puri, our Chief Regulatory Officer; Dr. Brian Gastman, our EVP of Medical Affairs, will be
#Iovance #Biotherapeutics #IOVA #Earnings #Call #Transcript